Owing to the deficiency of a protein called dystrophin, the
muscles of an individual are weakened, resulting in progressive
muscle degeneration, which is called Duchenne muscular
dystrophy. This medical disorder can be attributed to one of four
conditions called dystrophinopathies.
WILMINGTON, Del., July 16,
2024 /PRNewswire/ -- The projected advancement of the global
Duchenne muscular dystrophy market is expected to
traverse an impressive development path during the
forecasted period. The ecosystem is likely to encompass a CAGR
of 11.7% through 2034.
Owing to the surge in different demand drivers, the competitive
landscape will navigate through different prospective chances,
enabling the industry to reach USD 7.4
billion by 2034. The sector was valued at
USD 2.2 billion in 2023.
The progress of the industry is attributed to the rising
prevalence of Duchenne muscular dystrophy. With the growing number
of patients affected due to such a genetic disorder, the demand for
treatment for such disorders is surging. This factor drives the
industry size.
Statistics related to this rising number are indicative of the
growing market for Duchenne muscular dystrophy. North America and Europe combined forecasted that about 6 of
100,000 people are likely to be affected with the disease.
Request a PDF Sample of this Report
Now!
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=28145
With the proliferation of awareness campaigns, people have
started to become more alert regarding the muscular disorder. This
results in a rising number of patients approaching for medical
help, which elevates prospects for the said sector.
Key players in the Duchenne muscular dystrophy industry are
aiming to invest more in research and development projects. This
will help such players to find new therapies and treatments to
treat patients. Such developments will lead to the augmentation of
the industry.
New technologies like exon skipping technology are emerging in
the field, which benefits patients. Such a catalyst accelerates the
growth of the ecosystem and generates more prospects for existing
players.
Different tests, pertaining to the diseases, are gaining
momentum in the sector, which is expected to predict the
progression of the disease more accurately. As a result, more
patients will likely benefit from accurate diagnosis.
The growing investments in the research and development sector
are expected to fuel new inventions. Drug development and
repurposing are expected to gain momentum in the forecasted era,
attributing to the proliferation of the global Duchenne muscular
dystrophy market.
Government initiatives to consolidate the healthcare
infrastructure to cater to the diverse requirements of patients an
indicative of a better future for the said sector. With the medical
field being bolstered, better treatments in terms of efficiency and
efficacy can be provided to patients.
Duchenne Muscular Dystrophy Market Report
Scope:
Report
Coverage
|
Details
|
Forecast
Period
|
2024-2034
|
Base
Year
|
2020-2022
|
Size in 2023
|
US$ 2.2 Bn
|
Forecast (Value) in
2034
|
US$ 7.4 Bn
|
Growth Rate
(CAGR)
|
11.7 %
|
No. of
Pages
|
167
Pages
|
Segments
covered
|
By Treatment Type, By
End-user, By Region
|
Key Findings from the Market Report
- The competitive landscape of Duchenne muscular dystrophy is
classified based on different parameters. Based on the type of
treatment, steroid therapy is expected to gain traction. As
steroids can strengthen muscles, the therapy is expected to be used
widely.
- Molecular-based therapies leverage the generation of
dystrophin, which includes the use of exon-skipping therapies. This
helps the patient recover partially, albeit not fully, from the
disease.
- Physical therapy is expected to gain attention as such
treatments can be provided without frequent assistance from a
medical expert.
- Based on the end-user segment, hospitals are expected to govern
a large share of the industry. Due to cutting-edge facilities,
patients tend to rely more on hospitals.
Regional Profile
- With the growing healthcare infrastructure in developing
countries of Asia-Pacific, more
prospects will be created for the Duchenne muscular dystrophy
market.
- With spurring research activities in Europe, better medical treatments can be
provided to patients.
- The development of the healthcare sector and cutting-edge
technology will allow key players in the region to expand in the
industry.
Unlock Growth Potential in Your Industry! Download PDF
Brochure
-https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=28145
Competitive Landscape
The vast competitive landscape of Duchenne muscular dystrophy is
explored by key players using product launches, partnerships,
acquisitions, and many more.
- Pfizer Inc. is a key player that produces different drugs like
etomidate, Ampicillin Sodium, argatroban injection, and so on.
- F. Hoffmann-La Roche Ltd. offers many solutions, including
CellCept, Copegus, Avastin, and so on.
- Mylan N.V. operates in different areas like gastro and
transplant care, oncology, infectious diseases, and
dermatology.
Key Players
- Pfizer Inc.
- F. Hoffmann-La Roche Ltd.
- Mylan N.V.
- Fresenius Kabi AG
- Hikma Pharmaceuticals plc
- Novartis AG
- Teva Pharmaceutical Industries Ltd.
- Bristol Myers Squibb Company
- GSK plc
- Bayer AG
- Sun Pharmaceutical Industries Ltd.
- Boehringer Ingelheim
- Sanofi
- Sarepta Therapeutics Inc.
Key Developments in the Duchenne Muscular Dystrophy
Market
- In December 2023, Pfizer Inc.
acquired Seagen. The strategic move has leveraged a consolidated
position in the industry for the firm.
- In December 2023, F. Hoffmann-La
Roche Ltd. acquired LumiraDx's Point of Care technology.
Download our PDF brochure for comprehensive insights on this
report -
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=28145
Market Segmentation
Treatment Type
- Molecular-based Therapies
- Steroid Therapy
- Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
- Physical Therapy
- Others (Surgery, etc.)
End User
- Hospitals
- Specialty Clinics
- Others (Research Institutes, etc.)
Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Buy this Premium Research Report:
https://www.transparencymarketresearch.com/checkout.php?rep_id=28145<ype=S
More Trending Reports by Transparency Market Research
–
- Diabetes Devices Market - The global diabetes
devices market is projected to advance at a CAGR of 6.0%
from 2022 to 2031.
- Vaccines Market - The global vaccines market is
projected to expand at a CAGR of 4.2% during the forecast
period from 2023 to 2031.
- Laser Capture Microdissection Market: Market for
Laser Capture Microdissection is expected to grow at a CAGR
of 10.7% from 2024 to 2034 and reach US$
739.6 Mn by the end of 2034.
About Transparency Market Research
Transparency Market Research, a global market research
company registered at Wilmington, Delaware, United States, provides custom research and
consulting services. Our exclusive blend of quantitative
forecasting and trends analysis provides forward-looking insights
for thousands of decision makers. Our experienced team of Analysts,
Researchers, and Consultants use proprietary data sources and
various tools & techniques to gather and analyses
information.
Our data repository is continuously updated and revised by a
team of research experts, so that it always reflects the latest
trends and information. With a broad research and analysis
capability, Transparency Market Research employs rigorous primary
and secondary research techniques in developing distinctive data
sets and research material for business reports.
Contact:
Transparency Market Research Inc.
CORPORATE HEADQUARTER
DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware
19801 USA
Tel: +1-518-618-1030
USA – Canada Toll Free:
866-552-3453
Website: https://www.transparencymarketresearch.com
Email: sales@transparencymarketresearch.com
Follow Us: LinkedIn | Twitter |
Blog | YouTube
Logo:
https://mma.prnewswire.com/media/1682871/TMR_Logo_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/duchenne-muscular-dystrophy-market-on-track-to-surpass-us-7-4-billion-by-2034-at-cagr-of-11-7--analysis-by-transparency-market-research-inc-302198214.html